Regeneron Reports Phase 2 Data for Blinatumomab in Prostate cancer

Regeneron today announced Phase 2 results for Blinatumomab in patients with Prostate cancer. The study demonstrated that Blinatumomab demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Prostate cancer and support the continued development of Blinatumomab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Blinatumomab was consistent with previous observations, with no new safety signals identified.